No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GSK GlaxoSmithKline
- 44.980
- +0.100+0.22%
Close May 17 16:00 ET
- 44.770
- -0.210-0.47%
Post 19:33 ET
91.71BMarket Cap16.31P/E (TTM)
45.090High44.740Low1.88MVolume44.850Open44.880Pre Close84.66MTurnover0.10%Turnover Ratio14.81P/E (Static)2.04BShares45.54752wk High5.23P/B88.41BFloat Cap32.07952wk Low1.47Dividend TTM1.97BShs Float45.547Historical High3.26%Div YieldTTM0.78%Amplitude6.509Historical Low44.961Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSK plc (NYSE:GSK) confirmed the sale of 385.3 million shares in Haleon plc (NYSE:HLN) for $1.58 billion. The shares represented around 4.2% of the issued share capital of Haleon.Following the settlem
GSK Sale of Remaining Haleon Stake Nets More Than $1.5B
GlaxoSmithKline Pharma India Posts Higher Q4 Adjusted Profit on Strong Sales
Trending Tickers: Tesla, Reddit, Walmart and GSK
GlaxoSmithKline (GSK.US) will sell all remaining shares in Haleon (HLN.US)
British pharmaceutical company GlaxoSmithKline announced on Thursday that it plans to sell all of its remaining shares in consumer care company Haleon.
GSK PLC: Shares Are Equivalent to Around 4.2% of Haleon's Share Capital
GSK PLC: Shares Are Equivalent to Around 4.2% of Haleon's Share Capital
Comments
Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
$AbbVie(ABBV.US$ +189%
$Bristol-Myers Squibb(BMY.US$ +175%
$Johnson & Johnson(JNJ.US$ +95%
$AstraZeneca(AZN.US$ +78%
$NVM +45%
$Merck & Co(MRK.US$ +37%
$ROCHE HOLDING AG(RHHBY.US$ +27%
$Pfizer(PFE.US$ +13%
$GlaxoSmithKline(GSK.US$ +13%
----- $SPDR S&P 500 ETF(SPY.US$ +12% -----
$Sanofi(SNY.US$ +3%
Source: Arjun Murthy on the HR app!
3
1
A look at one of the major acquisition deals YTD…👇
$MRTX
Acquired By: Bristol-Myers Squibb $Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$ $GlaxoSmithKline(GSK.US$
$MRTX
Acquired By: Bristol-Myers Squibb $Bristol-Myers Squibb(BMY.US$
Date: Jan. 23, 2024
Price: $4.8B
$AbbVie(ABBV.US$ $GlaxoSmithKline(GSK.US$
5
1
$GlaxoSmithKline(GSK.US$ One day up, next 3-4 days will go down again
Goldman Sachs' Chief Global Equity Strategist Peter Oppenheimer finds the GRANOLAS' outperformance impressive on a risk-adjusted basis. They can benefit from the shift towards passive investment as they outperform when passive funds see more inflows.
1
Citi analyst Andrew Baum predicts Blenrep will be a standard care for refractory multiple myeloma patients for the next five years, assuming the DREAMM-8 trial meets its primary goal.
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
Xiaobie : how do you read TRIPLE?